All go for Progen

JUNE 2010

EMBATTLED drug developer Progen Pharmaceuticals (PGL) has been granted a European patent for the preparation and use of its cancer therapeutic Muparfostat (PI-88).

Progen CEO Sue MacLeman says the patent grant will give the company greater coverage in a major pharmaceutical market.

Progen has also announced it plans to sublicence the technology to Taiwanese company Medigen Biotech Corp.

Amid board restructures and uncertainty for the biotech’s future, PGL shares have fallen by around 40 per cent in the last 12 months.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane biotech to trial world-first COVID-19 immunotherapy treatment

Brisbane and Seattle-based biotechnology company Implicit Bioscie...

Federal Court finds Google misled consumers on data collection

Federal Court finds Google misled consumers on data collection

The Federal Court has found Google misled consumers about persona...

Redflow charging up ahead of next-gen battery launch

Redflow charging up ahead of next-gen battery launch

Redflow (ASX: RFX) is gearing up to launch the next generation of...

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

Mayne Pharma breakthrough as FDA approves new contraceptive with plant-based estrogen

A bet made by Mayne Pharma (ASX: MYX) in 2019 has paid off today ...